Search Results

Dapiglutide is a once-weekly, subcutaneous dual GLP-1/GLP-2 receptor agonist being investigated for the treatment of obesity. This first-in-class molecule is designed to take advantage of the weight-loss effects of GLP-1 agonist and the additional benefit of a  GLP-2 agonist on improving intestinal barrier function and addressing co-morbidities associated with low-grade inflammation seen in obesity.

The SCALE Kids trial (NCT04775082) is the first randomized, placebo-controlled, phase 3 study examining the use of liraglutide 3.0 mg in children aged 6 to <12 years with obesity. The trial addresses a crucial gap in paediatric obesity treatment, aiming to establish the safety and efficacy of liraglutide in children under 12, where no approved medications exist, alongside lifestyle interventions such as diet and physical activity.

Polycystic ovary syndrome (PCOS) is a multifactorial, multifaceted syndrome that affects women across all ages from adolescence to post-menopause. It is reported to be the most common endocrinopathy in women of the reproductive age group.1 The nature of this syndrome is such that it requires support and intervention from multiple medical and allied specialties. The treatment […]

Dr John Doupis is a former clinical research fellow of the Joslin Diabetes Center, Harvard Medical School, in Boston, MA, USA and scientific partner in Beth Israel Deaconess Foot Center Harvard Medical School, Boston, MA. Currently, he is directing the Diabetes Division and Clinical Research Center of Iatriko P. Falirou Medical Center in Athens, Greece. […]